“LEQEMBI(R)” (lecanemab) IV Repairs Dosing for the Remedy of Early Alzheimer’s Disease Accredited in China

TOKYO and CAMBRIDGE, Mass., Sept. 29, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) offered this day that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic establish: lecanemab) has been favorite for once every four weeks intravenous (IV) upkeep dosing by the Nationwide Scientific Merchandise Administration (NMPA) in China.In January 2024…
Learn More